Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Sell
43
NAMS Quote, Financials, Valuation and Earnings
Last price:
$25.92
Seasonality move
:
41.96%
Day range:
$25.71 - $26.33
52-week range:
$11.03 - $27.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
69.34x
P/B ratio:
6.31x
Volume:
459.5K
Avg. volume:
1.2M
1-year change:
130.89%
Market cap:
$2.4B
Revenue:
$14.1M
EPS (TTM):
-$2.25
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NAMS
NewAmsterdam Pharma Co NV
|
$1.8M | -$0.49 | 114.05% | -14.08% | $43.16 |
|
ARGX
argenx SE
|
$539.9M | $0.06 | 57.19% | -44.75% | $658.94 |
|
MRUS
Merus NV
|
$8.7M | -$0.85 | -4.27% | -10.77% | $86.07 |
|
PHAR
Pharming Group
|
$76M | -$0.00 | 0.91% | -- | -- |
|
PRQR
ProQR Therapeutics NV
|
$12.3M | -$0.14 | 25.16% | -54.98% | $4.10 |
|
QURE
uniQure NV
|
$7.1M | -$1.01 | 194.09% | -62.87% | $30.72 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NAMS
NewAmsterdam Pharma Co NV
|
$25.86 | $43.16 | $2.4B | -- | $0.00 | 0% | 69.34x |
|
ARGX
argenx SE
|
$626.31 | $658.94 | $37.5B | -- | $0.00 | 0% | 20.53x |
|
MRUS
Merus NV
|
$42.07 | $86.07 | $2.9B | -- | $0.00 | 0% | 72.01x |
|
PHAR
Pharming Group
|
$10.22 | -- | $693.3M | -- | $0.00 | 0% | 2.65x |
|
PRQR
ProQR Therapeutics NV
|
$2.79 | $4.10 | $295.5M | -- | $0.00 | 0% | 11.73x |
|
QURE
uniQure NV
|
$17.50 | $30.72 | $853M | -- | $0.00 | 0% | 29.62x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NAMS
NewAmsterdam Pharma Co NV
|
-- | 0.873 | -- | 10.37x |
|
ARGX
argenx SE
|
-- | -0.253 | -- | 7.52x |
|
MRUS
Merus NV
|
-- | 1.520 | -- | 7.94x |
|
PHAR
Pharming Group
|
29.71% | -1.043 | 17.05% | 2.76x |
|
PRQR
ProQR Therapeutics NV
|
15.29% | -1.974 | 3.39% | 2.29x |
|
QURE
uniQure NV
|
47.8% | 0.153 | 21.27% | 6.18x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NAMS
NewAmsterdam Pharma Co NV
|
-- | -$23.9M | -54.26% | -51.66% | -81.99% | -$12.6M |
|
ARGX
argenx SE
|
$514.2M | $16.2M | -5.47% | -6.01% | 15.47% | -$147M |
|
MRUS
Merus NV
|
-- | -$72.2M | -47.97% | -47.97% | -613.59% | -$80.7M |
|
PHAR
Pharming Group
|
$68M | $4.1M | -5.33% | -8.24% | 6.03% | $9.4M |
|
PRQR
ProQR Therapeutics NV
|
-- | -$9.7M | -59.09% | -66.59% | -230.39% | -$7.1M |
|
QURE
uniQure NV
|
$1.3M | -$40.2M | -96.96% | -154.29% | -1215.48% | -$45.3M |
NewAmsterdam Pharma Co NV vs. Competitors
-
Which has Higher Returns NAMS or ARGX?
argenx SE has a net margin of -57.19% compared to NewAmsterdam Pharma Co NV's net margin of 15.95%. NewAmsterdam Pharma Co NV's return on equity of -51.66% beat argenx SE's return on equity of -6.01%.
Company Gross Margin Earnings Per Share Invested Capital NAMSNewAmsterdam Pharma Co NV-- -$0.18 $378.9M ARGXargenx SE89.7% $1.39 $4.3B -
What do Analysts Say About NAMS or ARGX?
NewAmsterdam Pharma Co NV has a consensus price target of $43.16, signalling upside risk potential of 66.9%. On the other hand argenx SE has an analysts' consensus of $658.94 which suggests that it could grow by 5.21%. Given that NewAmsterdam Pharma Co NV has higher upside potential than argenx SE, analysts believe NewAmsterdam Pharma Co NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings NAMSNewAmsterdam Pharma Co NV5 0 0 ARGXargenx SE13 2 0 -
Is NAMS or ARGX More Risky?
NewAmsterdam Pharma Co NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison argenx SE has a beta of 0.589, suggesting its less volatile than the S&P 500 by 41.058%.
-
Which is a Better Dividend Stock NAMS or ARGX?
NewAmsterdam Pharma Co NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewAmsterdam Pharma Co NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAMS or ARGX?
NewAmsterdam Pharma Co NV quarterly revenues are $29.1M, which are smaller than argenx SE quarterly revenues of $573.2M. NewAmsterdam Pharma Co NV's net income of -$16.6M is lower than argenx SE's net income of $91.4M. Notably, NewAmsterdam Pharma Co NV's price-to-earnings ratio is -- while argenx SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewAmsterdam Pharma Co NV is 69.34x versus 20.53x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAMSNewAmsterdam Pharma Co NV69.34x -- $29.1M -$16.6M ARGXargenx SE20.53x -- $573.2M $91.4M
-
Which has Higher Returns NAMS or MRUS?
Merus NV has a net margin of -57.19% compared to NewAmsterdam Pharma Co NV's net margin of -848.67%. NewAmsterdam Pharma Co NV's return on equity of -51.66% beat Merus NV's return on equity of -47.97%.
Company Gross Margin Earnings Per Share Invested Capital NAMSNewAmsterdam Pharma Co NV-- -$0.18 $378.9M MRUSMerus NV-- -$1.46 $703.3M -
What do Analysts Say About NAMS or MRUS?
NewAmsterdam Pharma Co NV has a consensus price target of $43.16, signalling upside risk potential of 66.9%. On the other hand Merus NV has an analysts' consensus of $86.07 which suggests that it could grow by 104.59%. Given that Merus NV has higher upside potential than NewAmsterdam Pharma Co NV, analysts believe Merus NV is more attractive than NewAmsterdam Pharma Co NV.
Company Buy Ratings Hold Ratings Sell Ratings NAMSNewAmsterdam Pharma Co NV5 0 0 MRUSMerus NV12 0 0 -
Is NAMS or MRUS More Risky?
NewAmsterdam Pharma Co NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merus NV has a beta of 1.071, suggesting its more volatile than the S&P 500 by 7.125%.
-
Which is a Better Dividend Stock NAMS or MRUS?
NewAmsterdam Pharma Co NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewAmsterdam Pharma Co NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAMS or MRUS?
NewAmsterdam Pharma Co NV quarterly revenues are $29.1M, which are larger than Merus NV quarterly revenues of $11.8M. NewAmsterdam Pharma Co NV's net income of -$16.6M is higher than Merus NV's net income of -$99.9M. Notably, NewAmsterdam Pharma Co NV's price-to-earnings ratio is -- while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewAmsterdam Pharma Co NV is 69.34x versus 72.01x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAMSNewAmsterdam Pharma Co NV69.34x -- $29.1M -$16.6M MRUSMerus NV72.01x -- $11.8M -$99.9M
-
Which has Higher Returns NAMS or PHAR?
Pharming Group has a net margin of -57.19% compared to NewAmsterdam Pharma Co NV's net margin of -1.38%. NewAmsterdam Pharma Co NV's return on equity of -51.66% beat Pharming Group's return on equity of -8.24%.
Company Gross Margin Earnings Per Share Invested Capital NAMSNewAmsterdam Pharma Co NV-- -$0.18 $378.9M PHARPharming Group90.89% -$0.02 $321.2M -
What do Analysts Say About NAMS or PHAR?
NewAmsterdam Pharma Co NV has a consensus price target of $43.16, signalling upside risk potential of 66.9%. On the other hand Pharming Group has an analysts' consensus of -- which suggests that it could grow by 164.19%. Given that Pharming Group has higher upside potential than NewAmsterdam Pharma Co NV, analysts believe Pharming Group is more attractive than NewAmsterdam Pharma Co NV.
Company Buy Ratings Hold Ratings Sell Ratings NAMSNewAmsterdam Pharma Co NV5 0 0 PHARPharming Group0 0 0 -
Is NAMS or PHAR More Risky?
NewAmsterdam Pharma Co NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pharming Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NAMS or PHAR?
NewAmsterdam Pharma Co NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewAmsterdam Pharma Co NV pays -- of its earnings as a dividend. Pharming Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAMS or PHAR?
NewAmsterdam Pharma Co NV quarterly revenues are $29.1M, which are smaller than Pharming Group quarterly revenues of $74.8M. NewAmsterdam Pharma Co NV's net income of -$16.6M is lower than Pharming Group's net income of -$1M. Notably, NewAmsterdam Pharma Co NV's price-to-earnings ratio is -- while Pharming Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewAmsterdam Pharma Co NV is 69.34x versus 2.65x for Pharming Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAMSNewAmsterdam Pharma Co NV69.34x -- $29.1M -$16.6M PHARPharming Group2.65x -- $74.8M -$1M
-
Which has Higher Returns NAMS or PRQR?
ProQR Therapeutics NV has a net margin of -57.19% compared to NewAmsterdam Pharma Co NV's net margin of -210.98%. NewAmsterdam Pharma Co NV's return on equity of -51.66% beat ProQR Therapeutics NV's return on equity of -66.59%.
Company Gross Margin Earnings Per Share Invested Capital NAMSNewAmsterdam Pharma Co NV-- -$0.18 $378.9M PRQRProQR Therapeutics NV-- -$0.11 $32.9M -
What do Analysts Say About NAMS or PRQR?
NewAmsterdam Pharma Co NV has a consensus price target of $43.16, signalling upside risk potential of 66.9%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $4.10 which suggests that it could grow by 186.74%. Given that ProQR Therapeutics NV has higher upside potential than NewAmsterdam Pharma Co NV, analysts believe ProQR Therapeutics NV is more attractive than NewAmsterdam Pharma Co NV.
Company Buy Ratings Hold Ratings Sell Ratings NAMSNewAmsterdam Pharma Co NV5 0 0 PRQRProQR Therapeutics NV2 1 0 -
Is NAMS or PRQR More Risky?
NewAmsterdam Pharma Co NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.240, suggesting its less volatile than the S&P 500 by 75.965%.
-
Which is a Better Dividend Stock NAMS or PRQR?
NewAmsterdam Pharma Co NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewAmsterdam Pharma Co NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAMS or PRQR?
NewAmsterdam Pharma Co NV quarterly revenues are $29.1M, which are larger than ProQR Therapeutics NV quarterly revenues of $4.2M. NewAmsterdam Pharma Co NV's net income of -$16.6M is lower than ProQR Therapeutics NV's net income of -$8.9M. Notably, NewAmsterdam Pharma Co NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewAmsterdam Pharma Co NV is 69.34x versus 11.73x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAMSNewAmsterdam Pharma Co NV69.34x -- $29.1M -$16.6M PRQRProQR Therapeutics NV11.73x -- $4.2M -$8.9M
-
Which has Higher Returns NAMS or QURE?
uniQure NV has a net margin of -57.19% compared to NewAmsterdam Pharma Co NV's net margin of -1940.45%. NewAmsterdam Pharma Co NV's return on equity of -51.66% beat uniQure NV's return on equity of -154.29%.
Company Gross Margin Earnings Per Share Invested Capital NAMSNewAmsterdam Pharma Co NV-- -$0.18 $378.9M QUREuniQure NV55.36% -$0.91 $106.9M -
What do Analysts Say About NAMS or QURE?
NewAmsterdam Pharma Co NV has a consensus price target of $43.16, signalling upside risk potential of 66.9%. On the other hand uniQure NV has an analysts' consensus of $30.72 which suggests that it could grow by 75.56%. Given that uniQure NV has higher upside potential than NewAmsterdam Pharma Co NV, analysts believe uniQure NV is more attractive than NewAmsterdam Pharma Co NV.
Company Buy Ratings Hold Ratings Sell Ratings NAMSNewAmsterdam Pharma Co NV5 0 0 QUREuniQure NV8 2 0 -
Is NAMS or QURE More Risky?
NewAmsterdam Pharma Co NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.895, suggesting its less volatile than the S&P 500 by 10.539%.
-
Which is a Better Dividend Stock NAMS or QURE?
NewAmsterdam Pharma Co NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewAmsterdam Pharma Co NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAMS or QURE?
NewAmsterdam Pharma Co NV quarterly revenues are $29.1M, which are larger than uniQure NV quarterly revenues of $2.3M. NewAmsterdam Pharma Co NV's net income of -$16.6M is higher than uniQure NV's net income of -$44.4M. Notably, NewAmsterdam Pharma Co NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewAmsterdam Pharma Co NV is 69.34x versus 29.62x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAMSNewAmsterdam Pharma Co NV69.34x -- $29.1M -$16.6M QUREuniQure NV29.62x -- $2.3M -$44.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
